Hostname: page-component-7479d7b7d-wxhwt Total loading time: 0 Render date: 2024-07-11T05:12:19.801Z Has data issue: false hasContentIssue false

INTRODUCTION: Rethinking Pharmaceutical Policies in Latin America and the Caribbean: An Overview

Published online by Cambridge University Press:  29 December 2023

Martín Rama
Affiliation:
MARTÍN RAMA, WASHINGTON, DC, USA
Verónica Vargas
Affiliation:
VERÓNICA VARGAS, CAMBRIDGE, MA, USA AND SANTIAGO, CHILE

Abstract

The demographic and epidemiological transitions are driving pharmaceutical expenditures up in Latin American and the Caribbean, with much of the cost falling on households. The domestic development and manufacturing of bio-similars could make medicines more affordable.

Type
Symposium Articles
Copyright
© 2023 The Author(s)

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Vargas, V., Rama, M., and Singh, R., “Pharmaceuticals in Latin America and the Caribbean: Players, Access, and Innovation Across Diverse Models,” 2022, Unpublished manuscript, The World Bank, Washington, DC, available at <http://hdl.handle.net/10986/36871> (last visited September 20, 2023).CrossRef+(last+visited+September+20,+2023).>Google Scholar
Cortez, R., Medici, A., and Singh, R., “Out-of-Pocket Pending and Financial Equity in the Access to Medicines in Latin America: Trends and Challenges: 2010-2020,” Journal of Law, Medicine, & Ethics 51, no. 3 (suppl.) (2023): 1738.Google Scholar
Ortiz-Prado, E., Izquierdo-Condoy, J.S., Vasconez-González, E., Dávila, G., Correa, T., and Fernández-Naranjo, R., “The Pharmaceutical Market for Biological Products in Latin America: A Comprehensive Analysis of Regional Sales Data,” Journal of Law, Medicine, & Ethics 51, no. 3 (suppl.) (2023): 3961.Google Scholar
Aguilera, B., Peña, S., and Morales, J. P., “Knowledge, Perceptions, and Utilization of Generics and Biosimilars in Latin America and the Caribbean: A Scoping Review,” Journal of Law, Medicine & Ethics 51, no. 3 (suppl.) (2023): 100115.Google Scholar
Vargas, V. and Darrow, J., “Pharmaceutical Innovation in Latin America and the Caribbean,” Journal of Law, Medicine & Ethics 51, no. 3 (suppl.) (2023): 148162.Google Scholar
Lavarello, P., Gutman, G., and Pita, J.J., “Biosimilars and Heterogeneous Technological Trajectories in the Argentine Biopharmaceutical Industry,” Journal of Law, Medicine & Ethics 51, no. 3 (suppl.) (2023): 116125.Google Scholar
Paranhos, J., Hasenclever, L., and Perin, F.S., “The Brazilian Pharmaceutical Industry: Actors, Institutions and Policies,” Journal of Law, Medicine & Ethics 51, no. 3 (suppl.) (2023): 126135.Google Scholar
Villanueva, O.E. Pérez and Espiñeira, J.C. Albizu Campos, “The Development of Cuba’s Biotechnology: Mechanisms and Challenges,” Journal of Law, Medicine & Ethics 51, no. 3 (suppl.) (2023): 136147.Google Scholar
Basak, S.K., “From Pharmaceutical Innovation to Revenue Generation: The Asian Experience,” Journal of Law, Medicine & Ethics 51, no. 3 (suppl.) (2023): 6275.Google Scholar
Leopold, C., Poblete, S., and Vogler, S., “How to Price and to Reimburse Publicly Funded Medicines in Latin America? Lessons Learned from Europe,” Journal of Law, Medicine & Ethics 51, no. 3 (suppl.) (2023): 7691.Google Scholar
Iunes, R. and Junior, A.A. Guerra, “On the Judicialization of Health and Access to Medicines in Latin America,” Journal of Law, Medicine & Ethics 51, no. 3 (suppl.) (2023): 9299.Google Scholar
See Vargas, et al., supra note 1.Google Scholar